Granules India Ltd

(GRANULES)

Granules India Faces Regulatory Challenges Amid Buy Recommendations - 13 Sep, 2024

Granules India is addressing USFDA observations at its Gagillapur site, leading to a 23% stock decline. Analysts still recommend buying with a target of Rs 680, expecting strong earnings growth despite regulatory hurdles.

Granules India Stock Plummets on USFDA Concerns - 12 Sep, 2024

Granules India shares fell over 16% after the USFDA issued six observations from an inspection at its Gagillapur facility, raising investor concerns. The company is committed to addressing these issues promptly.

Granules India Shares Drop After USFDA Observations - 09 Sep, 2024

Granules India Ltd's shares declined by 4% following the USFDA's six observations from an inspection at its Gagillapur facility. The company is committed to addressing these observations promptly.

Granules India Completes USFDA Inspection with Observations - 08 Sep, 2024

Granules India announced the completion of a USFDA inspection at its Gagillapur facility, which resulted in six observations. The company is committed to addressing these observations promptly.

Granules India Faces FDA Observations at Gagillapur Plant - 07 Sep, 2024

Granules India Ltd's Gagillapur facility completed a US FDA inspection with six observations. The company is committed to addressing these promptly. Despite this, Granules reported significant profit growth in Q1 FY25.

Granules India Faces FDA Audit Amid Strong Performance - 03 Sep, 2024

Granules India Ltd experienced a brief stock decline due to a surprise FDA audit at its Gagilapur facility, which generates over 70% of its revenue. Despite this, the company reported a 20% revenue growth in Q1 FY25 and a tripling of net profit, driven by strong US demand. The stock remains a high performer with a 127% return over the past year.

Granules India Ltd Shows Strong Breakout Potential - 30 Aug, 2024

Granules India Ltd has experienced a 100% rally over the past year and recently achieved a Pole & Flag breakout. Experts suggest short-term traders consider buying the stock, targeting Rs 777 within the next 3-4 weeks.

Granules India Exhibits Bullish Breakout Trend - 29 Aug, 2024

Granules India has experienced a consolidation breakout, supported by strong volume and bullish RSI. Analysts expect the stock to target Rs 770, with support at Rs 685.

Granules India Shares Drop After Facility Inspection - 27 Aug, 2024

Granules India Ltd. experienced a significant decline in share price following a surprise inspection at its Gagilapur facility, which accounts for over 70% of revenue. The facility has 11 pending ANDAs for the US market, raising concerns among investors.

KR Choksey Upgrades Granules India to BUY - 21 Aug, 2024

KR Choksey has upgraded Granules India to a BUY rating with a target price of Rs 769, citing strong growth in FDFs and improved revenue and net income projections for FY24-FY26E.

Granules India Secures FDA Approval for Pediatric Drug - 20 Aug, 2024

Granules India announced FDA approval for its Glycopyrrolate Oral Solution, aimed at treating pediatric patients with neurological conditions causing drooling. This approval enhances Granules' presence in the U.S. market.